Literature DB >> 29188853

Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries.

R F Buckley1, K P Sparks, K V Papp, M Dekhtyar, C Martin, S Burnham, R A Sperling, D M Rentz.   

Abstract

BACKGROUND: As prevention trials for Alzheimer's disease move into asymptomatic populations, identifying older individuals who manifest the earliest cognitive signs of Alzheimer's disease is critical. Computerized cognitive testing has the potential to replace current gold standard paper and pencil measures and may be a more efficient means of assessing cognition. However, more empirical evidence about the comparability of novel computerized batteries to paper and pencil measures is required.
OBJECTIVES: To determine whether two computerized IPad batteries, the NIH Toolbox Cognition Battery and Cogstate-C3, similarly predict subtle cognitive impairment identified using the Preclinical Alzheimer Cognitive Composite (PACC). DESIGN, SETTING, PARTICIPANTS: A pilot sample of 50 clinically normal older adults (Mage=68.5 years±7.6, 45% non-Caucasian) completed the PACC assessment, and the NIH Toolbox and Cogstate-C3 at research centers of Massachusetts General and Brigham and Women's Hospitals. Participants made 3-4 in-clinic visits, receiving the PACC first, then the NIH Toolbox, and finally the Cogstate-C3.>= 0.5SD), versus subtle cognitive impairment (<0.5SD). Composites for each computerized battery were created using principle components analysis, and compared with the PACC using non-parametric Spearman correlations. Logistic regression analyses were used to determine which composite was best able to classify subtle cognitive impairment from typical performance.
RESULTS: The NIH Toolbox formed one composite and exhibited the strongest within-battery alignment, while the Cogstate-C3 formed two distinct composites (Learning-Memory and Processing Speed-Attention). The NIH Toolbox and C3 Learning-Memory composites exhibited positive correlations with the PACC (ρ=0.49, p<0.001; ρ=0.58, p<0.001, respectively), but not the C3 Processing Speed-Attention composite, ρ=-0.18, p=0.22. The C3 Learning-Memory was the only composite that classified subtle cognitive impairment, and demonstrated the greatest sensitivity (62%) and specificity (81%) for that subtle cognitive impairment.
CONCLUSIONS: Preliminary findings suggest that the NIH Toolbox has the advantage of showing the strongest overall clustering and alignment with standardized paper-and-pencil tasks. By contrast, Learning-Memory tasks within the Cogstate-C3 battery have the greatest potential to identify cross-sectional, subtle cognitive impairment as defined by the PACC.

Entities:  

Keywords:  Cognitionzzm321990; aging; computerized testing; neuropsychology

Mesh:

Year:  2017        PMID: 29188853      PMCID: PMC5726304          DOI: 10.14283/jpad.2017.1

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  30 in total

1.  New and different approaches needed for the design and execution of Alzheimer's clinical trials.

Authors:  Maria C Carrillo; Bruno Vellas
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

2.  Face-name associative memory performance is related to amyloid burden in normal elderly.

Authors:  Dorene M Rentz; Rebecca E Amariglio; J Alex Becker; Meghan Frey; Lauren E Olson; Katherine Frishe; Jeremy Carmasin; Jacqueline E Maye; Keith A Johnson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2011-06-12       Impact factor: 3.139

3.  Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old.

Authors:  Mary Sano; Susan Egelko; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Michael Donohue; Sarah Walter; Shelly Sun; Luis Sauceda-Cerda
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

Review 4.  The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Authors:  Reisa Sperling; Elizabeth Mormino; Keith Johnson
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

Review 5.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Aβ amyloid, cognition, and APOE genotype in healthy older adults.

Authors:  Yen Ying Lim; Kathryn A Ellis; David Ames; David Darby; Karra Harrington; Ralph N Martins; Colin L Masters; Christopher Rowe; Greg Savage; Cassandra Szoeke; Victor L Villemagne; Paul Maruff
Journal:  Alzheimers Dement       Date:  2012-11-14       Impact factor: 21.566

7.  Cognition assessment using the NIH Toolbox.

Authors:  Sandra Weintraub; Sureyya S Dikmen; Robert K Heaton; David S Tulsky; Philip D Zelazo; Patricia J Bauer; Noelle E Carlozzi; Jerry Slotkin; David Blitz; Kathleen Wallner-Allen; Nathan A Fox; Jennifer L Beaumont; Dan Mungas; Cindy J Nowinski; Jennifer Richler; Joanne A Deocampo; Jacob E Anderson; Jennifer J Manly; Beth Borosh; Richard Havlik; Kevin Conway; Emmeline Edwards; Lisa Freund; Jonathan W King; Claudia Moy; Ellen Witt; Richard C Gershon
Journal:  Neurology       Date:  2013-03-12       Impact factor: 9.910

8.  Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia.

Authors:  David S Knopman; Rosebud O Roberts; Yonas E Geda; V Shane Pankratz; Teresa J H Christianson; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2009-11-05       Impact factor: 3.282

9.  The UK Biobank.

Authors:  Paul M Matthews; Cathie Sudlow
Journal:  Brain       Date:  2015-12       Impact factor: 13.501

Review 10.  Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review.

Authors:  Dorene M Rentz; Mario A Parra Rodriguez; Rebecca Amariglio; Yaakov Stern; Reisa Sperling; Steven Ferris
Journal:  Alzheimers Res Ther       Date:  2013-11-21       Impact factor: 6.982

View more
  25 in total

1.  EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

Authors:  P Aisen; J Touchon; R Amariglio; S Andrieu; R Bateman; J Breitner; M Donohue; B Dunn; R Doody; N Fox; S Gauthier; M Grundman; S Hendrix; C Ho; M Isaac; R Raman; P Rosenberg; R Schindler; L Schneider; R Sperling; P Tariot; K Welsh-Bohmer; M Weiner; B Vellas
Journal:  J Prev Alzheimers Dis       Date:  2017

2.  Psychometric Properties of the NIH Toolbox Cognition Battery in Healthy Older Adults: Reliability, Validity, and Agreement with Standard Neuropsychological Tests.

Authors:  Emmi P Scott; Anne Sorrell; Andreana Benitez
Journal:  J Int Neuropsychol Soc       Date:  2019-07-01       Impact factor: 2.892

3.  ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.

Authors:  Sandra Weintraub; Tatiana Karpouzian-Rogers; John Devin Peipert; Cindy Nowinski; Jerry Slotkin; Katy Wortman; Emily Ho; Emily Rogalski; Cynthia Carlsson; Bruno Giordani; Felicia Goldstein; John Lucas; Jennifer J Manly; Dorene Rentz; David Salmon; Beth Snitz; Hiroko H Dodge; Michaela Riley; Fatima Eldes; Vitali Ustsinovich; Richard Gershon
Journal:  Alzheimers Dement       Date:  2021-11-17       Impact factor: 16.655

4.  Computerized paired associate learning performance and imaging biomarkers in older adults without dementia.

Authors:  Corinne Pettigrew; Anja Soldan; Rostislav Brichko; Yuxin Zhu; Mei-Cheng Wang; Kwame Kutten; Murat Bilgel; Susumu Mori; Michael I Miller; Marilyn Albert
Journal:  Brain Imaging Behav       Date:  2021-10-23       Impact factor: 3.224

5.  Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.

Authors:  Nikki H Stricker; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Shehroo B Pudumjee; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 6.  Adapting Alzheimer Disease and Related Dementias Clinical Research Evaluations in the Age of COVID-19.

Authors:  Maria Loizos; Judith Neugroschl; Carolyn W Zhu; Clara Li; Margaret Sewell; Michael T Kinsella; Amy Aloysi; Hillel Grossman; Corbett Schimming; Jane Martin; Mary Sano
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Apr-Jun 01       Impact factor: 2.703

7.  Patient perspectives of the experience of a computerized cognitive assessment in a clinical setting.

Authors:  Julie M Robillard; Jen-Ai Lai; Julia M Wu; Tanya L Feng; Sherri Hayden
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-10

8.  Utility of the iPad NIH Toolbox Cognition Battery in a clinical trial of older adults.

Authors:  Carolyn M Parsey; Justina E Bagger; Emily H Trittschuh; Angela J Hanson
Journal:  J Am Geriatr Soc       Date:  2021-08-03       Impact factor: 5.562

Review 9.  Current advances in digital cognitive assessment for preclinical Alzheimer's disease.

Authors:  Fredrik Öhman; Jason Hassenstab; David Berron; Michael Schöll; Kathryn V Papp
Journal:  Alzheimers Dement (Amst)       Date:  2021-07-20

10.  Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non-demented older adults.

Authors:  Beth E Snitz; Dana L Tudorascu; Zheming Yu; Elizabeth Campbell; Brian J Lopresti; Charles M Laymon; Davneet S Minhas; Neelesh K Nadkarni; Howard J Aizenstein; William E Klunk; Sandra Weintraub; Richard C Gershon; Ann D Cohen
Journal:  Alzheimers Dement (Amst)       Date:  2020-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.